Cargando…
Undisclosed payments by pharmaceutical manufacturers to authors of inflammatory bowel disease guidelines in the United States
BACKGROUND: Payments from pharmaceutical drug manufacturers to authors of clinical practice guidelines (CPGs) may have an impact on their recommendations. In this study, we aimed to evaluate the accuracy of financial conflict of interest (FCOI) declarations among authors of Inflammatory Bowel Diseas...
Autores principales: | Al Sulais, Eman, Alsahafi, Majid, AlAmeel, Turki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656332/ https://www.ncbi.nlm.nih.gov/pubmed/34755712 http://dx.doi.org/10.4103/sjg.sjg_426_21 |
Ejemplares similares
-
Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
por: Al Sulais, Eman, et al.
Publicado: (2020) -
Methotrexate in inflammatory bowel disease: A primer for gastroenterologists
por: AlAmeel, Turki, et al.
Publicado: (2022) -
Barriers to research productivity among gastroenterologists and hepatologists in Saudi Arabia
por: AlSardi, Mais, et al.
Publicado: (2020) -
The Prevalence of Irritable Bowel Syndrome Among Board-Certified Medical Doctors In Saudi Arabia: A Cross-sectional Study
por: AlAmeel, Turki, et al.
Publicado: (2019) -
Risk of neutropenia in inflammatory bowel disease patients treated with TNF inhibitors: A single-center, retrospective cohort study
por: AlAskar, Dimah, et al.
Publicado: (2020)